At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 60 enrolled
Drug / intervention
Ciraparantag +2 moredrug
Likely dose
Apixaban 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2 Placebo-Controlled, Single-Site, Single-Blind Study of Apixaban Reversal by Ciraparantag as Measured by WBCT
Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.·interventional·Posted Sep 20, 2017·Updated Sep 2, 2025
In Brief
A Phase 2 clinical trial evaluating Ciraparantag, Placebo, and 1 other intervention for Healthy. Completed, enrolled 60 participants across 1 site.
Detailed Summary
This study is a randomized, single-blind, placebo-controlled study to assess the efficacy and safety of ciraparantag administered to healthy volunteers anticoagulated with apixaban measuring clotting times using Whole Blood Clotting Time (WBCT).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
Enrollment StartAug 2017
First PostedSep 2017
Primary CompletionAug 2019
TodayJul 2026
First PostedSep 20, 2017
Enrollment StartAug 30, 2017
Primary CompletionAug 5, 2019
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 8.8 years ago
Interventions
Ciraparantagdrug
Ciraparantag (administered over 10 minutes)
Placebodrug
Saline for injection
Apixabandrug
Apixaban 10mg given twice daily (q12h)